United Therapeutics Corporation Share-based Payment Arrangement, Amount Capitalized
United Therapeutics Corporation (UTHR) reported Share-based Payment Arrangement, Amount Capitalized of $1.60 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement
us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount · last filed 2026-02-25
- United Therapeutics Corporation share-based payment arrangement, amount capitalized for fiscal 2025 was $1.60M, a 14.29% increase from fiscal 2024.
- United Therapeutics Corporation share-based payment arrangement, amount capitalized for fiscal 2024 was $1.40M, a 7.69% increase from fiscal 2023.
- United Therapeutics Corporation share-based payment arrangement, amount capitalized for fiscal 2023 was $1.30M, a 0.00% change from fiscal 2022.
- United Therapeutics Corporation share-based payment arrangement, amount capitalized for fiscal 2022 was $1.30M, a 30.00% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Amount Capitalized 12 month |
|---|---|
| 2025-12-31 | $1.60M 10-K · filed 2026-02-25 |
| 2024-12-31 | $1.40M 10-K · filed 2026-02-25 |
| 2023-12-31 | $1.30M 10-K · filed 2026-02-25 |
| 2022-12-31 | $1.30M 10-K · filed 2025-02-26 |
| 2021-12-31 | $1.00M 10-K · filed 2024-02-21 |
| 2020-12-31 | $1.00M 10-K · filed 2023-02-22 |
| 2019-12-31 | $700.00K 10-K · filed 2022-02-24 |
| 2018-12-31 | $700.00K 10-K · filed 2021-02-24 |
| 2017-12-31 | $400.00K 10-K · filed 2020-02-26 |
| 2016-12-31 | $200.00K 10-K · filed 2019-02-27 |
| 2015-12-31 | $7.10M 10-K · filed 2018-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |